Santhera Eyes US Market Potential After DMD Candidate Tests Positive
Top-Line Phase IIb Results For Vamorolone
Just under a year since Santhera restructured after disappointing late-stage clinical results with another DMD candidate, the Switzerland-headquartered company has reported positive top-line results in the condition with licensed-in vamorolone, and is planning for commercialization in late 2022/early 2023.
